SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

Ratings Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

Equities

300760

CNE100003G67

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
285.1 ^CNY	-0.26%		+4.60%	-1.89%

Apr. 17	Mindray Says It Is Compliant with International Trade Rules Ahead of EU Probe	MT
Mar. 12	Nomura Adjusts Shenzhen Mindray Bio-Medical’s Price Target to 441.20 Yuan From 423.39 Yuan, Keeps at Buy	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

With an expected P/E ratio at 29.79 and 24.79 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.63%	47.71B	B+
THERMO FISHER SCIENTIFIC	+8.78%	220B	B
DANAHER CORPORATION	+8.24%	185B	B-
INTUITIVE SURGICAL, INC.	+11.16%	133B	B-
BOSTON SCIENTIFIC CORPORATION	+26.12%	107B	A-
SIEMENS HEALTHINEERS AG	-0.08%	62.91B	A-
EDWARDS LIFESCIENCES CORPORATION	+16.21%	53.34B	B+
AGILENT TECHNOLOGIES, INC.	-1.11%	40.29B	A
GE HEALTHCARE TECHNOLOGIES INC.	+12.16%	39.57B	-
RESMED, INC.	+6.84%	26.99B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes